Iovance Biotherapeutics Inc [IOVA] stock prices are up 1.66% to $10.09 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IOVA shares have gain 35.92% over the last week, with a monthly amount glided 15.52%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on July 29, 2024, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $10 from $19. Previously, Goldman started tracking the stock with Buy rating on November 20, 2023, and set its price target to $12. On September 18, 2023, Barclays reiterated its Overweight rating and revised its price target to $18 on the stock. Wells Fargo upgraded its rating to a Overweight and increased its price target to $17 on May 30, 2023. Piper Sandler upgraded its rating to Overweight for this stock on January 27, 2023, and upped its price target to $14. In a note dated December 09, 2022, Goldman downgraded an Neutral rating on this stock and revised its target price from $20 to $6.
The stock price of Iovance Biotherapeutics Inc [IOVA] has been fluctuating between $3.21 and $18.33 over the past year. Currently, Wall Street analysts expect the stock to reach $21.57 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $10.09 at the most recent close of the market. An investor can expect a potential return of 113.78% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
The Iovance Biotherapeutics Inc [NASDAQ:IOVA] reported sales of 32.77M for trailing twelve months, representing a surge of 12969.75%. Gross Profit Margin for this corporation currently stands at -1.07% with Operating Profit Margin at -14.01%, Pretax Profit Margin comes in at -13.61%, and Net Profit Margin reading is -13.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.65 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.59 points at the first support level, and at 9.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.57, and for the 2nd resistance point, it is at 11.05.
Ratios To Look Out For
It’s worth pointing out that Iovance Biotherapeutics Inc [NASDAQ:IOVA]’s Current Ratio is 5.15. Further, the Quick Ratio stands at 4.85, while the Cash Ratio is 2.44. Considering the valuation of this stock, the price to sales ratio is 93.41, the price to book ratio is 3.90.
Transactions by insiders
Recent insider trading involved Rothbaum Wayne P., Director, that happened on Feb 20 ’24 when 5.0 million shares were purchased. Director, MCPEAK MERRILL A completed a deal on Feb 20 ’24 to buy 0.25 million shares. Meanwhile, Director Dukes Iain D. bought 32000.0 shares on Feb 20 ’24.
